Top

Published in:

01-08-2012 | PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Is Psoriatic Arthritis a Result of Abnormalities in Acquired or Innate Immunity?

Authors: Rik J. Lories, Kurt de Vlam

Published in: Current Rheumatology Reports | Issue 4/2012

Abstract

Psoriatic arthritis is a common chronic inflammatory joint disease in which both inflammation and tissue damage contribute to the patient’s outcome. Abnormal activation of the innate and the adaptive immune system contributes to the chronic disease process. Novel insights into these immune pathways are further corroborated by genetic evidence. In this review, we compare the current paradigm of psoriasis to mechanisms that likely play a role in psoriatic arthritis and provide an overview of the role of immune mechanisms in the different features of the disease.

Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61(10):1373–8.PubMedCrossRef

Gladman DD. Natural history of psoriatic arthritis. Bailliere’s Clin Rheumatol. 1994;8(2):379–94.CrossRef

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509.PubMedCrossRef

• Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity. 2011;35(6):857–69. This excellent review clearly illustrates the role of the skin as an immune barrier and basic mechanisms of chronic immune-mediated skin diseases.PubMedCrossRef

Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9.PubMedCrossRef

Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–94.PubMedCrossRef

Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8(9):950–7.PubMedCrossRef

Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597–607.PubMed

Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78.PubMedCrossRef

10.

Nash P, Mease PJ, Braun J, van der Heijde D. Seronegative spondyloarthropathies: to lump or split? Annals Rheum Dis. 2005;64 Suppl 2:ii9–13.CrossRef

11.

Dougados M. Psoriatic arthritis: is it for real? Joint Bone Spine. 2007;74(4):311–2.PubMedCrossRef

12.

Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659–72.PubMedCrossRef

13.

Tan AL, McGonagle D. Psoriatic arthritis: correlation between imaging and pathology. Joint Bone Spine. 2010;77(3):206–11.PubMedCrossRef

14.

McGonagle D, Lories RJ, Tan AL, Benjamin M. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum. 2007;56(8):2482–91.PubMedCrossRef

15.

Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol. 2011;7(12):700–7.PubMedCrossRef

16.

Pattison E, Harrison BJ, Griffiths CE, et al. Environmental risk factors for the development of psoriatic arthritis: results from a case–control study. Ann Rheum Dis. 2008;67(5):672–6.PubMedCrossRef

17.

Kamradt T, Schubert D. The role and clinical implications of G6PI in experimental models of rheumatoid arthritis. Arthritis Res Ther. 2005;7(1):20–8.PubMedCrossRef

18.

Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med. 2008;205(2):331–7.PubMedCrossRef

19.

McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23 Suppl 1:9–13.PubMedCrossRef

20.

Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis—a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–6.CrossRef

21.

Lande R, Giacomini E, Serafini B, et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol. 2004;173(4):2815–24.PubMed

22.

Jongbloed SL, Lebre MC, Fraser AR, et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther. 2006;8(1):R15.PubMedCrossRef

23.

•• Wenink MH, Santegoets KC, Butcher J, et al. Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis Rheum. 2011;63(11):3313–22. This article reports on a novel finding in PsA. Dendritic cells appear defective in producing cytokines after in vitro stimulation. This defective function may play an essential role in the pathogenesis of the disease.PubMedCrossRef

24.

Rambukkana A, Das PK, Witkamp L, et al. Antibodies to mycobacterial 65-kDa heat shock protein and other immunodominant antigens in patients with psoriasis. J Investig Dermatol. 1993;100(1):87–92.PubMedCrossRef

25.

Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58(8):2307–17.PubMedCrossRef

26.

Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876–85.PubMedCrossRef

27.

Yeremenko N, Baeten D. IL-17 in spondyloarthritis: is the T-party over? Arthritis Res Ther. 2011;13(3):115.PubMedCrossRef

28.

• Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64(1):99–109. All too often, IL-17 is uniquely associated with T cells. This article shows that this is not a correct assumption.PubMedCrossRef

29.

Glatigny S, Fert I, Blaton MA, et al. Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats. Arthritis Rheum. 2012;64(1):110–20.PubMedCrossRef

30.

Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis. 2000;59(4):263–8.PubMedCrossRef

31.

Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939–48.PubMedCrossRef

32.

Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–40.PubMedCrossRef

33.

Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661–8.PubMedCrossRef

34.

Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94.PubMedCrossRef

35.

Vandooren B, Noordenbos T, Ambarus C, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum. 2009;60(4):966–75.PubMedCrossRef

36.

Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R569–80.PubMedCrossRef

37.

Lories RJ, Baeten DL. Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S10–4.PubMed

38.

Lories RJ. Joint homeostasis, restoration, and remodeling in osteoarthritis. Best Pract Res Clin Rheumat. 2008;22(2):209–20.CrossRef

39.

Siannis F, Farewell VT, Cook RJ, et al. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis. 2006;65(4):478–81.PubMedCrossRef

40.

van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56(8):2698–707.PubMedCrossRef

41.

van Kuijk AW, DeGroot J, Koeman RC, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PloS one. 2010, 5(9).

42.

Schett G, David JP. The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol. 2010;6(12):698–706.PubMedCrossRef

43.

Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast formation. Nat Med. 2011;17(10):1235–41.PubMedCrossRef

44.

Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–4.PubMedCrossRef

45.

Okamoto K, Takayanagi H. Osteoclasts in arthritis and Th17 cell development. Int Immunopharmacol. 2011;11(5):543–8.PubMedCrossRef

46.

Pollinger B, Junt T, Metzler B, et al. Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol. 2011;186(4):2602–12.PubMedCrossRef

47.

Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111(6):821–31.PubMed

48.

Colucci S, Brunetti G, Cantatore FP, et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol. 2007;212(1):47–55.PubMedCrossRef

49.

Chiu YG, Shao T, Feng C, et al. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther. 2010;12(1):R14.PubMedCrossRef

50.

Vandooren B, Cantaert T, Noordenbos T, et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58(3):718–29.PubMedCrossRef

51.

Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther. 2009;11(2):221.PubMedCrossRef

52.

Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol. 2010;6(2):75–81.PubMedCrossRef

53.

Lories RJ, Derese I, Ceuppens JL, Luyten FP. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003;48(10):2807–18.PubMedCrossRef

54.

Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156–63.PubMedCrossRef

55.

Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum. 2007;56(2):489–97.PubMedCrossRef

56.

Eder L, Chandran V, Gladman DD. Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. J Rheumatol. 2011;38(6):1066–70.PubMedCrossRef

57.

•• O’Rielly DD, Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol. 2011;7(12):718–32. This is an excellent summary of recent progress in the genetics of PsA, adequately discussed in comparison with psoriasis. Moreover, an interesting section on pharmacogenomics is included.PubMedCrossRef

58.

Sonder SU, Saret S, Tang W, et al. IL-17-induced NF-kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol Chem. 2011;286(15):12881–90.PubMedCrossRef

59.

Bowes J, Eyre S, Flynn E, et al. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis. 2011;70(6):1016–9.PubMedCrossRef

60.

Eder L, Chandran V, Pellett F, et al. IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann Rheum Dis. 2011;70(9):1594–8.PubMedCrossRef

Title: Is Psoriatic Arthritis a Result of Abnormalities in Acquired or Innate Immunity?
Authors: Rik J. Lories
Kurt de Vlam
Publication date: 01-08-2012
Publisher: Current Science Inc.
Published in: Current Rheumatology Reports / Issue 4/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-012-0257-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is Psoriatic Arthritis a Result of Abnormalities in Acquired or Innate Immunity?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?

Belimumab and the Clinical Data

How Can Psoriatic Arthritis Be Diagnosed Early?

What Have Genome-Wide Studies Told Us About Psoriatic Arthritis?

Data Quality Challenges in Systemic Lupus Erythematosus Trials: How Can This Be Optimized?

Cardiovascular Mortality in Psoriasis and Psoriatic Arthritis: Epidemiology, Pathomechanisms, Therapeutic Implications, and Perspectives

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page